Study of LJP 394 (Abetimus Sodium) in Lupus Patients
NCT00390091
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
abetimus sodium (LJP 394)
Sponsor
La Jolla Pharmaceutical Company